Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

83.3%

-3.2% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

5 of 5 completed trials have results

Key Signals

5 with results

Enrollment Performance

Analytics

Phase 1
4(66.7%)
Phase 2
2(33.3%)
6Total
Phase 1(4)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT02323100Phase 1Terminated

Glycerol Phenylbutyrate Corrector Therapy For CF (Cystic Fibrosis)

Role: collaborator

NCT02666768Phase 2Completed

ACTIMMUNE in Intermediate Osteopetrosis

Role: collaborator

NCT04125459Active Not Recruiting

Assessing the Role of the NLRP3 Inflammasome in Intercritical Gout

Role: collaborator

NCT03112590Phase 1Completed

Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer

Role: collaborator

NCT02584608Phase 2Completed

Use of ACTIMMUNE in Patients With ADO2

Role: collaborator

NCT02614456Phase 1Completed

Combination of Interferon-gamma and Nivolumab for Advanced Solid Tumors

Role: collaborator

NCT01881984Phase 1Completed

Use of Ravicti™ in Patients With MCAD Deficiency With the 985A>G (K304E) Mutation

Role: collaborator

All 7 trials loaded